Generic Drugs: World Market 2013-2023 - Central Coast News KION/KCBA

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Reportlinker

NEW YORK, March 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generic Drugs: World Market 2013-2023

http://www.reportlinker.com/p0663864/Generic-Drugs-World-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug

Report Details

Your guide to trends and sales potential for generics

Where's the generic drugs market heading? Visiongain's updated report gives you revenue predictions to 2023. There you find data, trends, opportunities and commercial prospects.

That new study lets you assess forecasted sales at overall world market and national level. You discover the potential of the generics market, seeing how, why and where it can grow. As pharma patents expire, much opportunity remains.

Forecasts and other analyses to help you find growth potentials

In our report you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (inc. SWOT), progress, competition, developments and business outlooks. You receive 48 tables, 36 charts and six research interviews.

Our work lets you investigate the most lucrative areas of the generics industry. See the outlook for that large, expanding pharmaceutical segment. Spending restraints will benefit it.

You can stay ahead in knowledge, benefiting your research and analyses. The following sections show what you discover in our study.

Leading national markets - where will high growth occur?

In addition to analyses of the overall world market, you discover individual revenue forecasts for seven developed national markets, with sales data from 2011 to 2023. • US• Japan• Germany, France, UK, Italy and Spain (EU5).

Also our work shows you individual forecasts to 2023 for seven developing countries:

• Brazil, Russian Federation, India and China (BRIC nations)

• Turkey, South Korea and Mexico.

There will be growth in established pharma markets and in developing countries. Our analyses show that Japan, India, Mexico and Brazil, in particular, will achieve high revenue growth to 2016. You see what's likely to happen. Events will influence that market.

What issues will affect the generics industry?

Our study discusses matters affecting that sector from 2012 onwards:• US, European and Japanese regulations• Authorised, branded and other generics, including modified products• Patent expiries and business strategies, including patenting challenges• Generic drug prescribing linked to budgetary constraints• Growing consumer acceptance of generic medicines• M&A activities, including entry of big pharma companies.

Also you find coverage of these aspects:

• European pricing systems and generic penetration

• Price changes, trends, prescribers and pharmacies

• Patient co-payment

• ANDAs and approvals

• Pathways to the market for biosimilars

• Product differentiation.

See what the future holds. You find discussions of commercial, technological, regulatory and economic issues, with emphasis on the competitive landscape and sales predictions.

Leading companies and market value in 2013

Overall world revenue for generic medicines will reach $127.8bn in 2013, our report forecasts. Rising demand for prescription drugs, expanding healthcare coverage, payers favouring generics and changes to prescribing will increase sales to 2023.

Also, our investigation discusses these specialty companies and others:

• Teva Pharmaceutical Industries

• Sandoz (Novartis)

• Mylan

• Apotex

• Hospira

• Watson Pharmaceuticals.

From this decade onwards, many opportunities will arise for generics specialists and other pharma companies producing those medicines. You see how revenues can increase.

Nine ways Generic Drugs: World Market 2013-2023 benefits you

To sum up, our report gives you the following knowledge on the topic:• Predicted revenues to 2023 for the overall world generics market - find the industry's prospects• Forecasting to 2023 for 14 countries in North America, Europe, Asia andLatin America - see national sales prospects• Profiles of 6 leading companies - hear about products, results and strategies• Opinions on the sector - discover our interviews with leaders in industry• IP policy and other regulations - see what affects market access and entry• Patent expiry - find prominent drug brands facing generic competition• Trends of prescribers and healthcare payers - assess developments• Competition and opportunities influencing sales - see what affects the future• Discussions of what stimulates and restrains the industry and market - find trends, drivers and restraints.

Benefit from our analyses, gaining information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely.

With our report you are less likely to fall behind in knowledge or miss opportunity. Discover how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.

Ordering now lets you investigate prospects to 2023 for generic medicines

Visiongain's study is for everyone needing analysis of the pharmaceutical industry and market. You find data, trends and predictions. Please ask for our report now.

Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Generic Drugs: Industry and Market Review

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to the World Generics Market

2.1 Generic Drugs (Generics)2.1.1 Authorised, Branded and True Generics2.2 The 'Evergreening' of Pharmaceuticals2.3 Restraints Facing the World Pharmaceutical Market2.4 Branded Pharmaceuticals: End of a Business Model?2.5 US Regulations2.5.1 Obtaining FDA Approval: NDAs and ANDAs2.5.2 The Hatch-Waxman Act Title 1: Promotion of Generic Drugs2.5.3 The Hatch-Waxman Act Title 2: Incentives for the Branded Industry2.5.4 Consequences of the Hatch-Waxman Act2.5.5 Me First: Timing as a Crucial Factor2.6 European Regulations2.6.1 Generics' Entry into the European Markets2.6.2 Further Protection of Branded Products in the European Market2.6.3 Variations among European Countries2.6.4 Moving Towards Standardisation2.6.5 The 8+2+1 Rule2.7 Japanese Regulations2.8 Compulsory Licensing2.9 Generic Drugs: Overview

3. The World Generic Drugs Market, 2013-2023

3.1 The World Generic Pharmaceuticals Market in 2011

3.2 Generic Products to Benefit from Patent Expiries

3.2.1 Sales Forecast for the World Generic Drugs Market, 2012-2016

3.2.2 Sales Forecast for the World Generic Drugs Market, 2017-2023

3.3 Global Market Breakdown, 2013-2023

4. Leading Companies in the World Generics Market

4.1 Teva Pharmaceutical Industries - Prospects from 20134.1.1 ANDAs and Approvals4.1.2 M&A Activity4.2 Sandoz (Novartis) - Prospects from 20134.3 Mylan - Prospects from 20134.3.1 Mylan's Acquisition of Bioniche Pharma Holdings4.3.2 Mylan's Acquires Exclusive Worldwide Rights to GSK's Advair, Diskus and Seretide4.4 Apotex - Prospects from 20134.5 Hospira - Prospects from 20134.5.1 Acquisition of Orchid's Generic Injectable Pharmaceutical Business4.5.2 Hospira's Acquisition of Javelin Pharma4.6 Watson Pharmaceuticals - Prospects from 20134.6.1 ANDAs and Approvals4.6.2 M&A Activity4.6.3 Eden Becomes Wholly-Owned Subsidiary of Watson4.6.4 Watson Acquires Specifar Pharmaceuticals 4.6.5 Purchase of Ascent Pharmahealth Gives Watson Strong Footprint inSoutheast Asia

5. The US Generics Market, 2013-2023

5.1 Analysis of the Current Market

5.2 The US Generics Market: Revenue Forecast 2013-2023

5.3 Regulatory Reform Can Keep the Market Growing

5.3.1 A New Pathway to the US Market for Biosimilars?

5.3.2 Reverse Payments

5.3.3 The ANDA Backlog

5.4 Growing Consumer Acceptance of Generic Medicines

5.5 Leading Companies in the US Generics Market

5.6 Concluding Remarks

6. Leading European Generics Markets, 2013-2023

6.1 Analysis of the Current Generics Market in Europe6.2 Revenue Prospects for European Generics Markets 2013-20236.2.1 The Two Categories of European Market6.2.2 European Pricing Systems and their Effect on Generic Penetration6.2.3 Patient Co-Payment6.2.4 Challenges with the European Regulatory Environment6.3 The German Generics Market6.3.1 German Generics Market: Sales Forecast 2013-20236.3.2 The Future of the German Generics Market6.4 The French Generics Market6.4.1 French Generics Market: Sales Forecast 2013-20236.4.2 The Future of the French Generics Market6.5 The UK Generics Market6.5.1 UK Generics Market: Sales Forecast 2013-20236.5.2 Generics Prescribing Linked to Increasing Budgetary Constraints6.5.3 Reducing Generic Drug Prices: the Drug Tariff System6.5.4 The Increasing Role of Pharmacists6.5.5 Easy Entry, Strong Price Competition6.5.6 The Future of the UK Generics Market6.6 The Italian Generics Market6.6.1 Italian Generics Market: Sales Forecast 2013-20236.6.2 Promoting Generic Penetration6.6.3 Prospects for the Italian Generics Market6.7 The Spanish Generics Market6.7.1 Spanish Generics Market: Sales Forecast 2013-20236.7.2 Challenges for the Spanish Market6.7.3 Prospects for the Spanish Generics Market6.8 Concluding Remarks

7. The Japanese Generics Market, 2013-2023

7.1 Analysis of the Current Market

7.2 Japanese Generics Market: Sales Forecast 2013-2023

7.3 Government Initiatives Have Driven Market Growth

7.3.1 Mergers and Acquisitions

7.4 Concluding Remarks

8. Emerging Generics Markets, 2013-2023

8.1 The EM-7: Pharma's Best Hope8.2 M&A as a Tactic for Entering the Generic Drugs Sector8.3 Turkish Generics Market: Sales Forecast 2013-20238.4 Brazilian Generics Market: Sales Forecast 2013-20238.5 Mexican Generics Market: Sales Forecast 2013-20238.6 South Korean Generics Market: Sales Forecast 2013-20238.7 Russian Federation Generics Market: Sales Forecast 2013-20238.7.1 Russian Federation Generics Market, 2013-20238.7.2 Analysis of the Russian Federation Market8.8 India - Market Prospects from 20138.8.1 Indian Generics Market: Sales Forecast 2013-20238.8.2 International Success of India's Pharmaceutical Industry8.9 China - Market Prospects from 20138.9.1 Chinese Generics Market: Sales Forecast 2013-20238.9.2 Chinese Generics Market: Discussion of Sector

9. World Generics Market: Strengths, Weaknesses, Opportunities and Threats

9.1 The Generics Sector Will Remain a High-Growth Area

9.2 Generics Offer Limited Profitability

9.3 Emerging Markets and Generics: The Pharma Industry's BiggestOpportunity?

9.4 The Generic Drug Market's Growth is Assured, but Some Threats Remain

10. Opinions from Our Survey - Research Interviews

10.1 James Harris, CEO, Healthcare Economics LLC, Florida, USA10.1.1 Main Challenges for the US Generics Market10.1.2 Pricing Trends in Generic Products10.1.3 On Authorised Generic Products10.1.4 Current State of Biogeneric (Biosimilar) Legislation in the US10.1.5 On Para 4 Challenges and Patent Cliff10.1.6 On Generics Market in the Next Decade10.2 Charlie Mayr, Generic Pharmaceutical Association (GPhA)10.2.1 The Value of the Generics Market10.2.2 Main Challenges for the US Generics Market10.2.3 On Growth Trend in Generic Products10.2.4 On US Pricing Trends in Generic Products10.2.5 On Authorised Generic Products10.2.6 On Biogeneric (Biosimilar) Products10.3 Anjan Selz, CEO, Finox10.3.1 Finox10.3.2 Challenges in Biosimilar Development10.3.3 Differences Between Europe and the US10.3.4 Product Differentiation10.3.5 Opportunities Existing in the Biosimilars Market10.4 Dr Robin Thorpe, Head, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC) [UK]10.4.1 Immunogenicity in Biosimilars10.4.2 Biosimilar Uptake in Europe10.4.3 Biosimilar Monoclonal Antibodies10.5 Cecil Nick, VP (Biotechnology), Parexel Consulting10.5.1 Challenges in Biosimilar Development10.5.2 Asian Biosimilar Development10.5.3 Biosimilar Interferons10.6 Dr Jason Kantor, Managing Director, RBC Capital Markets10.6.1 Challenges in Developing Biosimilars10.6.2 Biosimilar Pricing10.6.3 Next-Generation Antibody Therapies

11. Conclusions

11.1 The World Generics Market Will Continue to Expand

11.2 The Emerging National Markets Hold Much Promise

11.3 Biosimilars Have Promise, but Difficulties and Uncertainties Remain

11.4 Concluding Remarks

Appendices

Appendix A: Supplementary Information: Patent ExpiriesAppendix B: About VisiongainAppendix C: Visiongain Report Evaluation Form

List of Tables

Table 3.1 Generic Drugs Market: World Sales Forecast, 2011-2016

Table 3.2 Generic Drugs Market: World Sales Forecast, 2017-2023

Table 3.3 Generic Drugs Market: Developed Countries - Sales Forecasts, 2011-2023

Table 3.4 Generic Drugs Market: Emerging Countries - Sales Forecasts, 2011-2023

Table 4.1 Leading Companies in the World Generics Market: Sales and Market Shares, 2011

Table 4.2 The Top 10 Generics Market: M&A Deals, 2004-2010

Table 4.3 Sandoz Overview: Key Figures, 2009-2011

Table 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2010

Table 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2010

Table 5.3 US Generics Market: Sales Forecast, 2011-2016

Table 5.4 US Generics Market: Sales Forecast, 2017-2023

Table 6.1 German Generics Market: Sales Forecast, 2011-2016

Table 6.2 German Generics Market: Sales Forecast, 2017-2023

Table 6.3 French Generics Market: Sales Forecast, 2011-2016

Table 6.4 French Generics Market: Sales Forecast, 2017-2023

Table 6.5 UK Generics Market: Sales Forecast, 2011-2016

Table 6.6 UK Generics Market: Sales Forecast, 2017-2023

Table 6.7 Italian Generics Market: Sales Forecast, 2011-2016

Table 6.8 Italian Generics Market: Sales Forecast, 2017-2023

Table 6.9 Spanish Generics Market: Sales Forecast, 2011-2016

Table 6.10 Spanish Generics Market: Sales Forecast, 2017-2023

Table 7.1 Japanese Generics Market: Sales Forecast, 2011-2016

Table 7.2 Japanese Generics Market: Sales Forecast, 2017-2023

Table 8.1 Turkish Generics Market: Sales Forecast, 2011-2016

Table 8.2 Turkish Generics Market: Sales Forecast, 2017-2023

Table 8.3 Brazilian Generics Market: Sales Forecast, 2011-2016

Table 8.4 Brazilian Generics Market: Sales Forecast, 2017-2023

Table 8.5 Mexican Generics Market: Sales Forecast, 2011-2016

Table 8.6 Mexican Generics Market: Sales Forecast, 2017-2023

Table 8.7 South Korean Generics Market: Sales Forecast, 2011-2016

Table 8.8 South Korean Generics Market: Sales Forecast, 2017-2023

Table 8.9 Russian Federation Generics Market: Sales Forecast, 2011-2016

Table 8.10 Russian Federation Generics Market: Sales Forecast, 2017-2023

Table 8.11 Indian Generics Market: Sales Forecast, 2011-2016

Table 8.12 Indian Generics Market: Sales Forecast, 2017-2023

Table 8.13 Chinese Generics Market: Sales Forecast, 2011-2016

Table 8.14 Chinese Generics Market: Sales Forecast, 2017-2023

Table 9.1 SWOT Analysis of World Generic Drugs Market: Strengths and Weaknesses, 2013-2023

Table 9.2 SWOT Analysis of World Generic Drugs Market: Opportunities and Threats, 2013-2023

Table 11.1 Generic Drugs National Markets: Leading Developed Countries - Sales Forecasts, 2011, 2013, 2016, 2018, 2020 & 2023

Table 11.2 Generic Drugs National Markets: Leading Emerging Countries - Sales Forecasts, 2011, 2013, 2016, 2018, 2020 & 2023

Table A.1 Main Patent Expiries, 2011-2014

Table A.2 Main Patent Expiries by Number, 2011-2014

Table A.3 Main Patent Expiries, 2010

Table A.4 Main Patent Expiries, 2011

Table A.5 Main Patent Expiries, 2012

Table A.6 Main Patent Expiries, 2013

Table A.7 Main Patent Expiries, 2014

List of Figures

Figure 3.1 Generic Drugs Market: World Sales Forecast, 2011-2016

Figure 3.2 Generic Drugs Market: World Sales Forecast, 2017-2023

Figure 3.3 Generic Drugs Market: US and World Sales Forecasts, 2011-2023

Figure 3.4 Generic Drugs Market: Japan and Germany Sales Forecasts, 2011-2023

Figure 3.5 Generic Drugs Market: Top Five EU Countries Sales Forecasts, 2011-2023

Figure 3.6 Generic Drugs Market: Emerging Countries Sales Forecasts, 2011-2023

Figure 3.7 Generic Drugs Market: Sales Shares in Leading National Markets, 2011

Figure 3.8 Generic Drugs Market: Sales Shares in Leading National Markets, 2016

Figure 3.9 Generic Drugs Market: Sales Shares in Leading National Markets, 2019

Figure 3.10 Generic Drugs Market: Sales Shares in Leading National Markets, 2023

Figure 4.1 Leading Companies in the World Generics Market, 2011

Figure 4.2 Teva's Sales Shares by Product Line, 2011

Figure 4.3 Novartis' Business Segments Revenue Breakdown & Sandoz Share, 2011

Figure 4.4 Mylan's Sales by Therapeutic Category, 2011

Figure 4.5 Hospira's Sales by Geographical Region, 2011

Figure 4.6 Watson's Sales by Segment, 2011

Figure 5.1 US Generic Drug Market Penetration (%) by Volume, 2000-2010

Figure 5.2 US Generic Drug Market Penetration (%) by Revenue, 2000-2010

Figure 5.3 US Generics Market: Sales Forecast, 2011-2023

Figure 5.4 ANDAs Received, Approved and Tentatively Approved, 2005-2009

Figure 5.5 US Generics Market: Leading Companies by Prescription Volume, 2011

Figure 6.1 German Generics Market: Sales Forecast, 2011-2023

Figure 6.2 French Generics Market: Sales Forecast, 2011-2023

Figure 6.3 UK Generics Market: Sales Forecast, 2011-2023

Figure 6.4 Italian Generics Market: Sales Forecast, 2011-2023

Figure 6.5 Spanish Generics Market: Sales Forecast, 2011-2023

Figure 7.1 Japanese Generics Market: Sales Forecast, 2011-2023

Figure 8.1 Turkish Generics Market: Sales Forecast, 2011-2023

Figure 8.2 Brazilian Generics Market: Sales Forecast, 2011-2023

Figure 8.3 Mexican Generics Market: Sales Forecast, 2011-2023

Figure 8.4 South Korean Generics Market: Sales Forecast, 2011-2023

Figure 8.5 Russian Federation Generics Market: Sales Forecast, 2011-2023

Figure 8.6 Indian Generics Market: Sales Forecast, 2011-2023

Figure 8.7 Chinese Generics Market: Sales Forecast, 2011-2023

Figure 11.1 Generic Drugs Market: US and World Sales Forecasts, 2011-2023

Figure 11.2 Generic Drugs Market: Leading Countries - Sales Forecasts, 2011-2023

Companies Listed

Abbott Laboratories

Aché Laboratórios Farmacêuticos

Actavis

Altra Investments

Amgen

Andrx

Andrx Corporation

Apotex

APP Pharmaceuticals

Arrow Group

Ascent Pharmahealth

Asociación Española de Fabricantes de Sustancias y Especialidades Farmacéuticas Genéricas (AESEG)

Aspen

Assogenerici - Associazione Nazionale Industrie Farmaci Generici

AstraZeneca

Aurobindo Pharma

Barr Pharmaceuticals

Bayer HealthCare

Bedford Laboratories

Beijing MedPharm

Bioniche Pharma Holdings

Biopartners

Biotechnology Industry Organization (BIO)

Blue Cross Blue Shield Association (BCBSA)

BMP Sunstone

Boehringer Ingelheim

Bristol-Myers Squibb

British Generics Manufacturers Association (BGMA)

Cangene Corporation

Celltrion

Centers for Medicare and Medicaid Services

Cephalon

Chon Kun Dang

Cipla

Claris Lifesciences

CoGenesys

Committee for Medicinal Products for Human Use (CHMP)

Congressional Budget Office (CBO)

Corporación Infarmasa ("Infarmasa", Peru)

Corporación Infarmasa [Peru]

Daiichi Sankyo

Dey Pharma

DOC Generici

Dr. Reddy's Laboratories

Ebewe Pharma

Eden Biodesign

Egis

Eisai Pharmaceuticals

Eli Lilly

EMS Sigma Pharma

Eon Labs

Eurofarma Laboratorios

European Commission (EC)

European Court of Justice

European Generic Medicines Association (EGA)

European Medicines Agency (EMA/EMEA)

European Union (EU)

Famy Care

Farmacia del Ahorro

Farmacias Similares

Federal Trade Commission (FTC)

Finox

Food and Drug Administration (US FDA)

Fuji Pharma

Gedeon Richter

Genentech

Generic Pharmaceutical Association (GPhA)

German Association of Pharmacists (ABDA)

GlaxoSmithKline (GSK)

Glenmark Pharmaceuticals

Greenstone (Pfizer)

H. Lundbeck

Health, Education, Labor and Pensions (HELP, US Senate Committee)

Healthcare Economics LLC

Hexal

Hospira

Hospira Healthcare India

Intas Biopharmaceuticals

IVAX

Javelin Pharmaceuticals

Johnson & Johnson

Jubilant Organosys

Kowa Pharmaceuticals

Krka

Laboratorios Best

Laboratorios Kendrick

Lareq Pharma

Lek Pharmaceuticals

Lundbeck

Lupin Pharmaceuticals

MasterLek

Matrix

Matrix Laboratories

Mayne Pharma

Medi-Mart

Medley Pharmaceuticals

Merck & Co.

Merck KGaA

Ministry of Health, Labour and Welfare [Japan]

Mundipharma International

Mylan Institutional

Mylan Laboratories

Mylan Pharmaceuticals

Mylan Seiyaku

National Health Service (UK NHS)

National Institute for Biological Standards and Control (NIBSC, UK)

Nichi-iko Pharmaceutical

Nippon Chemiphar

Novartis

NOVN.V Hexal

Office of Generic Drugs (OGD, US FDA)

Onco Therapies

Orchid Chemicals & Pharmaceuticals

Oriel Therapeutics

Parexel Consulting

Pfizer

Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmstandard

Piramal Healthcare

Pliva

Purdue Pharma

Ranbaxy Laboratories

Ratiopharm

RBC Capital Markets

Roche

Samsung

Sanborns

Sandoz

Sanofi (formerly sanofi-aventis)

Sawai Pharmaceuticals

Shire Pharmaceuticals

SICOR

Sigma Pharmaceuticals

SK Chemicals

Specifar Pharmaceuticals SA

Stada Arzneimittel AG

Strides Arcolab

Sun Pharmaceuticals

Taisho Pharmaceutical Industries

Taiyo Pharmaceuticals

Takeda Pharmaceutical Company

Tecnofarma

Teva Parenteral Medicines

Teva Pharmaceutical Industries

The Rohatyn Group

Theramex

Topgen

Towa Pharmaceutical

UCB

UDL Laboratories

UK Department of Health

Veropharm

Vinca

Wal-Mart

Warner Chilcott

Watson Laboratories

Watson Pharmaceuticals

Wockhardt

World Trade Organization (WTO)

Wyeth

Zentiva

Zydus Cadila

To order this report:Generic_Drug Industry: Generic Drugs: World Market 2013-2023

Contact Clare: clare@reportlinker.com

US:(339) 368 6001

Intl:+1 339 368 6001

©2012 PR Newswire. All Rights Reserved.